MiRNAs-mediated cisplatin resistance in breast cancer

doi:10.1007/s13277-016-5216-6

Review

. 2016 Oct;37(10):12905-12913.

doi: 10.1007/s13277-016-5216-6. Epub 2016 Jul 22.

MiRNAs-mediated cisplatin resistance in breast cancer

Xiu Chen^{1

2}, Peng Lu³, Ying Wu⁴, Dan-Dan Wang², Siying Zhou², Su-Jin Yang^{1

2}, Hong-Yu Shen^{1

2}, Xiao-Hui Zhang⁵, Jian-Hua Zhao⁵, Jin-Hai Tang⁶

Affiliations

¹ The Fourth Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.
² Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China.
³ School of Public Health Nanjing Medical University, Longmiandadao101, Nanjing, China.
⁴ The First Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.
⁵ Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Baiziting42, Nanjing, China.
⁶ Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China. jschjhtang@163.com.

PMID: 27448297
DOI: 10.1007/s13277-016-5216-6

Review

MiRNAs-mediated cisplatin resistance in breast cancer

Xiu Chen et al. Tumour Biol. 2016 Oct.

. 2016 Oct;37(10):12905-12913.

doi: 10.1007/s13277-016-5216-6. Epub 2016 Jul 22.

Authors

Xiu Chen^{1

2}, Peng Lu³, Ying Wu⁴, Dan-Dan Wang², Siying Zhou², Su-Jin Yang^{1

2}, Hong-Yu Shen^{1

2}, Xiao-Hui Zhang⁵, Jian-Hua Zhao⁵, Jin-Hai Tang⁶

Affiliations

¹ The Fourth Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.
² Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China.
³ School of Public Health Nanjing Medical University, Longmiandadao101, Nanjing, China.
⁴ The First Clinical School of Nanjing Medical University, Baiziting42, Nanjing, China.
⁵ Center of Clinical Laboratory Science, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Baiziting42, Nanjing, China.
⁶ Department of General Surgery, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University and First Affiliated Hospital of Nanjing Medical University, 210009, Baiziting42, Nanjing, China. jschjhtang@163.com.

PMID: 27448297
DOI: 10.1007/s13277-016-5216-6

Abstract

Cisplatin is a widely used chemotherapeutic agent in breast cancer treatments with inevitable rapidly acquired resistance or intrinsically resistance. Enormous evidence points to the bioprocesses of resistant formation consisting of diverse miRNAs direct and indirect actions on relevant encoding genes. In this report, we overview detailed information on the miRNAs effect on cisplatin-induced resistance, including alterations in cell survival, modification of DNA damage response, changes in cellular uptake or efflux of the drug, altered DNA methylation, and perturbations in the miRNA biogenesis pathway. This will provide potential miRNA-targeted strategies for the treatment of breast cancer therapy and requires further clinical application.

Keywords: Breast; Cisplatin; Drug resistance; miRNAs.

PubMed Disclaimer

Cited by

Bioinformatics analysis of mRNA and miRNA microarray to identify the key miRNA-mRNA pairs in cisplatin-resistant ovarian cancer.
Xue B, Li S, Jin X, Liu L. Xue B, et al. BMC Cancer. 2021 Apr 23;21(1):452. doi: 10.1186/s12885-021-08166-z. BMC Cancer. 2021. PMID: 33892654 Free PMC article.
MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms.
Posch F, Prinz F, Balihodzic A, Mayr C, Kiesslich T, Klec C, Jonas K, Barth DA, Riedl JM, Gerger A, Pichler M. Posch F, et al. Cancers (Basel). 2021 Aug 8;13(16):3996. doi: 10.3390/cancers13163996. Cancers (Basel). 2021. PMID: 34439151 Free PMC article.
Evaluation of Chemotherapeutic Drugs for Treatment of (Cisplatin-Resistant) Germ Cell Cancer Cell Lines.
Skowron MA, Hoffmann MJ, Watolla MM, Nettersheim D. Skowron MA, et al. Methods Mol Biol. 2021;2195:99-111. doi: 10.1007/978-1-0716-0860-9_8. Methods Mol Biol. 2021. PMID: 32852760
MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.
Xu X, Yu S, Sun W, Qin X, Chen Y, Zhou L, Lou R, Dong S, Shen B, Wu J, Zang J, Cao H, Shi M, Zhang Q, Feng J. Xu X, et al. J Cancer Res Clin Oncol. 2018 Mar;144(3):431-438. doi: 10.1007/s00432-017-2562-8. Epub 2017 Dec 29. J Cancer Res Clin Oncol. 2018. PMID: 29288364
Interactions between anticancer active platinum complexes and non-coding RNAs/microRNAs.
Biersack B. Biersack B. Noncoding RNA Res. 2016 Oct 13;2(1):1-17. doi: 10.1016/j.ncrna.2016.10.001. eCollection 2017 Mar. Noncoding RNA Res. 2016. PMID: 30159416 Free PMC article. Review.

See all "Cited by" articles

References

1. EMBO J. 1994 Sep 15;13(18):4302-10 - PubMed
1. Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed
1. Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 - PubMed
1. Cell Physiol Biochem. 2013;31(1):113-22 - PubMed
1. Oncogene. 2011 Jun 2;30(22):2526-33 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] EMBO J. 1994 Sep 15;13(18):4302-10 - PubMed

[2] EMBO J. 1994 Sep 15;13(18):4302-10 - PubMed

[3] Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed

[4] Int J Cancer. 2015 Mar 1;136(5):E359-86 - PubMed

[5] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 - PubMed

[6] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3903-8 - PubMed

[7] Cell Physiol Biochem. 2013;31(1):113-22 - PubMed

[8] Cell Physiol Biochem. 2013;31(1):113-22 - PubMed

[9] Oncogene. 2011 Jun 2;30(22):2526-33 - PubMed

[10] Oncogene. 2011 Jun 2;30(22):2526-33 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

MiRNAs-mediated cisplatin resistance in breast cancer

Affiliations

MiRNAs-mediated cisplatin resistance in breast cancer

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical